The Cancer Genome Atlas project identified HER2 somatic mutations and gene amplification in 7% of patients with colorectal cancer. Introduction of the HER2 mutations S310F, L755S, V777L, V842I, and L866M into colon epithelial cells increased signaling pathways and anchorage-independent cell growth, indicating that they are activating mutations. Introduction of these HER2 activating mutations into colorectal cancer cell lines produced resistance to cetuximab and panitumumab by sustaining MAPK phosphorylation. HER2 mutants are potently inhibited by low nanomolar doses of the irreversible tyrosine kinase inhibitors neratinib and afatinib. HER2 gene sequencing of 48 cetuximab-resistant, quadruple (KRAS, NRAS, BRAF, and PIK3CA) wild-type (WT) colorectal cancer patient-derived xenografts (PDX) identified 4 PDXs with HER2 mutations. HER2-targeted therapies were tested on two PDXs. Treatment with a single HER2-targeted drug (trastuzumab, neratinib, or lapatinib) delayed tumor growth, but dual HER2-targeted therapy with trastuzumab plus tyrosine kinase inhibitors produced regression of these HER2-mutated PDXs.

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

GALIMI, Francesco;LETO, SIMONETTA MARIA;MIGLIARDI, GIORGIA;TRUSOLINO, Livio;BERTOTTI, Andrea
;
2015

Abstract

The Cancer Genome Atlas project identified HER2 somatic mutations and gene amplification in 7% of patients with colorectal cancer. Introduction of the HER2 mutations S310F, L755S, V777L, V842I, and L866M into colon epithelial cells increased signaling pathways and anchorage-independent cell growth, indicating that they are activating mutations. Introduction of these HER2 activating mutations into colorectal cancer cell lines produced resistance to cetuximab and panitumumab by sustaining MAPK phosphorylation. HER2 mutants are potently inhibited by low nanomolar doses of the irreversible tyrosine kinase inhibitors neratinib and afatinib. HER2 gene sequencing of 48 cetuximab-resistant, quadruple (KRAS, NRAS, BRAF, and PIK3CA) wild-type (WT) colorectal cancer patient-derived xenografts (PDX) identified 4 PDXs with HER2 mutations. HER2-targeted therapies were tested on two PDXs. Treatment with a single HER2-targeted drug (trastuzumab, neratinib, or lapatinib) delayed tumor growth, but dual HER2-targeted therapy with trastuzumab plus tyrosine kinase inhibitors produced regression of these HER2-mutated PDXs.
5
8
832
841
http://cancerdiscovery.aacrjournals.org/content/5/8/832.full
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527087/
afatinib, cetuximab, epidermal growth factor receptor 2, mitogen activated protein kinase, neratinib, trastuzumab, antibody response, cancer cell culture, cell growth, colony formation, colorectal cancer, controlled study, gene amplification, gene mutation, gene sequence,human cell, IC50, in vitro gene transfer, protein phosphorylation, quantitative assay, signal transduction, tumor growth, tumor regression, tumor xenograft, Western blotting
Kavuri, Shyam M; Jain, Naveen; Galimi, Francesco; Cottino, Francesca; Leto, Simonetta M; Migliardi, Giorgia; Searleman, Adam C; Shen, Wei; Monsey, John; Trusolino, Livio; Jacobs, Samuel A; Bertotti, Andrea*; Bose, Ron* (*Corresponding Authors)
File in questo prodotto:
File Dimensione Formato  
2015_HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment.pdf

Accesso riservato

Descrizione: Versione per MIUR
Tipo di file: PDF EDITORIALE
Dimensione 3.25 MB
Formato Adobe PDF
3.25 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1523247
Citazioni
  • ???jsp.display-item.citation.pmc??? 112
  • Scopus 188
  • ???jsp.display-item.citation.isi??? 182
social impact